At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 84 enrolled
Drug / intervention
Detralexdrug
Likely dose
Detralex 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Antiinflammatory Effects of Detralex (Daflon) in Patients With Chronic Venous Disease
In Brief
A Phase 4 clinical trial evaluating Detralex for Chronic Venous Insufficiency. Completed, enrolled 84 participants across 1 site.
Detailed Summary
Aim of the study: To investigate if there is a differences in expression of inflammatory markers in venous wall and blood among patients treated with Detralex and those not treated with Detralex (control group).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Venous Insufficiency
CountriesCroatia
CollaboratorsServier
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartAug 2012
Primary CompletionMay 2019
Study CompletionSep 2019
TodayJul 2026
First PostedJul 31, 2012
Enrollment StartAug 1, 2012
Primary CompletionMay 1, 2019
Study CompletionSep 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 13.9 years ago
Interventions
Detralexdrug
Detralex 500 mg twice daily for three month prior to surgery